Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
Holding BCDA?
Track your performance easily
BCDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.96 - $23.25
Previous Close$2.79
Volume1.11M
Average Volume (3M)827.40K
Market Cap
$10.58M
Enterprise Value$9.49M
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 06, 2024EPS Estimate
-$1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.33
Shares Outstanding2,123,876
10 Day Avg. Volume230,165
30 Day Avg. Volume827,403
Standard Deviation0.23
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-2.61
Price to Sales (P/S)13.16
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.71
Enterprise Value/Gross Profit19.89
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BioCardia News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim data from the company’s most advanced program, the Phase 3 CardiAMP HF, demonstrated significant reductions in heart death equivalents and non-fatal MACCE, and exhibited a greater efficacy in patients with elevated baseline NT-proBNP levels.
Financial SupportApproved Medicare reimbursements for the ongoing Phase 3 CardiAMP HF II and CardiAMP CMI trials benefit the company's cash-neutral strategy.
Regulatory ApprovalBiocardia announced that the FDA has approved the protocol amendment for the CardiAMP cell population analysis to be used in the ongoing Phase 3 CardiAMP HF II confirmatory trial in HFrEF patients.
Bears Say
Cash ResourcesCautious about cash resources, Biocardia ended the quarter with $0.95 million in cash.
Efficacy DataThere is an absence of near-term efficacy data readouts and regulatory decisions.
Future OutlookWhile vigilant of the future of the company based on its cash position, absence of near-term efficacy data readouts, and regulatory decisions.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $1.96 and its highest was $23.25 in the past 12 months.
What is BioCardia Inc’s market cap?
Currently, no data Available
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Nov 06, 2024 which is in 49 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Aug 13, 2024. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.78.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -$1.19.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 3,501,866 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went down -1.894%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
---
BioCardia Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Blogger Sentiment
Bullish
BCDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 32.4%
Last 30 Days ▲ 32.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.77%
Trailing 12-Months
Company Description
BioCardia Inc
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
---
BCDA Earnings Call
Q2 2024
0:00 / 0:00
---
BCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Best Analysts Covering BCDA
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-58.98%
reiterated a buy rating 29 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.98% per trade.
---